Determinants of HIV-1 broadly neutralizing antibody induction

Nature Medicine

Volumn 22, Issue 11, 2016, Pages 1260-1267

  Rusert, Peter ^a   Kouyos, Roger D ^a,b   Kadelka, Claus ^a,b   Ebner, Hanna ^a   Schanz, Merle ^a   Huber, Michael ^a   Braun, Dominique L ^a,b   Hozé, Nathanael ^c   Scherrer, Alexandra ^a,b   Magnus, Carsten ^a,c   Weber, Jacqueline ^a   Uhr, Therese ^a   Cippa, Valentina ^a   Thorball, Christian W ^d,e   Kuster, Herbert ^a,b   Cavassini, Matthias ^f   Bernasconi, Enos ^g   Hoffmann, Matthias ^h   Calmy, Alexandra ⁱ   Battegay, Manuel ^j   Rauch, Andri ^k   Yerly, Sabine ⁱ   Aubert, Vincent ^f   Klimkait, Thomas ^l   Böni, Jürg ^a   Fellay, Jacques ^d,e   Regoes, Roland R ^d   Günthard, Huldrych F ^a,b   Trkola, Alexandra ^a   Bucher, Heiner C ^m   Ciuffi, Angela ^f   Dollenmaier, Günther ⁿ   Egger, Matthias ^o   Elzi, Luigia ^j   Fehr, Jan ^b   Furrer, Hansjakob ^k   Fux, Christoph A ^p   Haerry, David ^q   Hasse, Barbara ^b   Hirsch, Hans H ^j,l   Hösli, Irene ^j   Kahlert, Christian ^h,r   Kaiser, Laurent ⁱ   Keiser, Oolivia ^o   Kovari, Helen ^b   Ledergerber, Bruno ^b   Martinetti, Gladys ^s   De Tejada, Begoña Martinez ⁱ   Marzolini, Catia ^j   Metzner, Karin J ^a,b   Müller, Nicolas ^b   Nicca, Dunja ^h,l   Pantaleo, Giuseppe ^f   Paioni, Paolo ^t   Rudin, Christoph ^u   Schmid, Patrick ^h   Speck, Roberto ^b   Stöckle, Marcel ^j   Tarr, Philip ^j   Vernazza, Pietro ^h   Wandeler, Gilles ^k   Weber, Rainer ^b   more..

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c ETH ZURICH   (Switzerland)

^d EPFL   (Switzerland)

^e SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^h CANTONAL HOSPITAL ST GALLEN   (Switzerland)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^j UNIVERSITY HOSPITAL BASEL   (Switzerland)

^k UNIVERSITY OF BERN   (Switzerland)

^l UNIVERSITY OF BASEL   (Switzerland)

^m UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁿ Center for Laboratory Medicine   (Switzerland)

^o UNIVERSITY OF BERN   (Switzerland)

^p CANTONAL HOSPITAL AARAU   (Switzerland)

^q Positive Council Switzerland   (Switzerland)

^r Kantonsspital St Gallen   (Switzerland)

^s Cantonal Institute of Microbiology   (Switzerland)

^t UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^u UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BROADLY NEUTRALIZING ANTIBODY; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; POLYSACCHARIDE; VIRUS RNA;

ADULT; ARTICLE; BINDING SITE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PLASMA; PRIORITY JOURNAL; VIRUS LOAD; BLACK PERSON; BLOOD; CAUCASIAN; DRUG DEVELOPMENT; GENETIC VARIATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LONGITUDINAL STUDY; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; STATISTICAL MODEL; SWITZERLAND; TIME FACTOR;

AFRICAN CONTINENTAL ANCESTRY GROUP; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; DRUG DISCOVERY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; POLYSACCHARIDES; PROSPECTIVE STUDIES; RNA, VIRAL; SWITZERLAND; TIME FACTORS; VIRAL LOAD;

EID: 84988698013     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4187     Document Type: Article

References (59)

1. Burton, D.R. & Mascola, J.R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16, 571-576 (2015).
2. Klein, F. et al. Antibodies in HIV-1 vaccine development and therapy. Science 341, 1199-1204 (2013).
3. Mascola, J.R. & Haynes, B.F. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254, 225-244 (2013).
4. Moore, P.L., Williamson, C. & Morris, L. Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol. 23, 204-211 (2015).
5. Caskey, M. et al. Viremia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487-491 (2015).
6. Lynch, R.M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).
7. Trkola, A. et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11, 615-622 (2005).
8. Scheid, J.F. et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535, 556-560 (2016).
9. Euler, Z. et al. Longitudinal analysis of early HIV-1-specifc neutralizing activity in an elite neutralizer and in fve patients who developed cross-reactive neutralizing activity. J. Virol. 86, 2045-2055 (2012).
10. Simek, M.D. et al. Human immunodefciency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identifed by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83, 7337-7348 (2009).
11. Burton, D.R. et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 12, 396-407 (2012).
12. + T cell decline and high viral load during acute infection. J. Virol. 85, 4828-4840 (2011).
13. Sather, D.N. et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodefciency virus type 1 infection. J. Virol. 83, 757-769 (2009).
14. Landais, E. et al. Broadly neutralizing antibody responses in a large longitudinal sub-Saharan HIV primary infection cohort. PLoS Pathog. 12, e1005369 (2016).
15. Klein, F. et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153, 126-138 (2013).
16. Kwong, P.D. & Mascola, J.R. Human antibodies that neutralize HIV-1: identifcation, structures and B cell ontogenies. Immunity 37, 412-425 (2012).
17. Doria-Rose, N.A. et al. Breadth of human-immunodefciency-virus-specifc neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84, 1631-1636 (2010).
18. Moore, P.L. et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 18, 1688-1692 (2012).
19. Bhiman, J.N. et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat. Med. 21, 1332-1336 (2015).
20. Doria-Rose, N.A. et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509, 55-62 (2014).
21. Liao, H.X. et al. Coevolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469-476 (2013).
22. Wu, X. et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593-1602 (2011).
23. Wibmer, C.K. et al. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 9, e1003738 (2013).
24. Cortez, V. et al. The broad neutralizing antibody responses after HIV-1 superinfection are not dominated by antibodies directed to epitopes common in single infection. PLoS Pathog. 11, e1004973 (2015).
25. Luo, S. & Perelson, A.S. Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising. Proc. Natl. Acad. Sci. USA 112, 11654-11659 (2015).
26. Piantadosi, A. et al. Breadth of neutralizing antibody response to human immunodefciency virus type 1 is affected by factors early in infection but does not infuence disease progression. J. Virol. 83, 10269-10274 (2009).
27. Derdeyn, C.A., Moore, P.L. & Morris, L. Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Curr. Opin. HIV AIDS 9, 210-216 (2014).
28. FH cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 39, 758-769 (2013).
29. Schoeni-Affolter, F. et al. Cohort profle: the Swiss HIV Cohort study. Int. J. Epidemiol. 39, 1179-1189 (2010).
30. Rieder, P. et al. Characterization of human immunodefciency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. Clin. Infect. Dis. 53, 1271-1279 (2011).
31. + lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126, 946-954 (1997).
32. Recher, M. et al. Deliberate removal of T cell help improves virus-neutralizing antibody production. Nat. Immunol. 5, 934-942 (2004).
33. Kelsoe, G., Verkoczy, L. & Haynes, B.F. immune system regulation in the induction of broadly neutralizing HIV-1 antibodies. Vaccines (Basel) 2, 1-14 (2014).
34. Kouyos, R.D. et al. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin. Infect. Dis. 52, 532-539 (2011).
35. Shankarappa, R. et al. Consistent viral evolutionary changes associated with the progression of human immunodefciency virus type 1 infection. J. Virol. 73, 10489-10502 (1999).
36. Kouyos, R.D. et al. Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. J. Infect. Dis. 201, 1488-1497 (2010).
37. von Wyl, V. et al. The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. J. Infect. Dis. 204, 1095-1103 (2011).
38. Montefori, D.C. et al. Demographic factors that infuence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J. Infect. Dis. 190, 1962-1969 (2004).
39. Chuang, G.Y. et al. Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. J. Virol. 87, 10047-10058 (2013).
40. Georgiev, I.S. et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 340, 751-756 (2013).
41. Goo, L., Chohan, V., Nduati, R. & Overbaugh, J. Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat. Med. 20, 655-658 (2014).
42. Ward, A.B. & Wilson, I.A. Insights into the trimeric HIV-1 envelope glycoprotein structure. Trends Biochem. Sci. 40, 101-107 (2015).
43. Yang, W.L. et al. Assessing the paradox between transmitted and acquired HIV type 1 drug resistance mutations in the Swiss HIV Cohort Study from 1998 to 2012. J. Infect. Dis. 212, 28-38 (2015).
44. Rieder, P. et al. HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS 24, 1177-1183 (2010).
45. Ragonnet-Cronin, M. et al. Genetic diversity as a marker for timing infection in HIV-infected patients: evaluation of a 6-month window and comparison with BED. J. Infect. Dis. 206, 756-764 (2012).
46. Andersson, E. et al. Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. Infect. Genet. Evol. 18, 125-131 (2013).
47. Taffé, P. & May, M. A joint back-calculation model for the imputation of the date of HIV infection in a prevalent cohort. Stat. Med. 27, 4835-4853 (2008).
48. Castro, K.G. et al. 1993 Revised classifcation system for HIV infection and expanded surveillance case defnition for AIDS among adolescents and adults. MMWR 41, RR-17 (CDC, 1992).
49. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
50. Yoon, H. et al. CATNAP: a tool to compile, analyze and tally neutralizing antibody panels. Nucleic Acids Res. 43, W213-W219 (2015).
51. Rusert, P. et al. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J. Exp. Med. 208, 1419-1433 (2011).
52. Walker, L.M. et al. A limited number of antibody specifcities mediate broad and potent serum neutralization in selected HIV-1-infected individuals. PLoS Pathog. 6, e1001028 (2010).
53. Mikell, I. et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7, e1001251 (2011).
54. Binley, J.M. et al. Profling the specifcity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodefciency virus type 1 subtypes B and C. J. Virol. 82, 11651-11668 (2008).
55. Dhillon, A.K. et al. Dissecting the neutralizing antibody specifcities of broadly neutralizing sera from human immunodefciency virus type 1-infected donors. J. Virol. 81, 6548-6562 (2007).
56. Hraber, P. et al. Impact of clade, geography and age of the epidemic on HIV-1 neutralization by antibodies. J. Virol. 88, 12623-12643 (2014).
57. Hraber, P. et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28, 163-169 (2014).
58. Campbell, M.J. & Swinscow, T.D.V. Statistics at Square One (Wiley-Blackwell/BMJ Books, 2009).
59. Rand, W.M. Objective criteria for evaluation of clustering methods. J. Am. Stat. Assoc. 66, 846-850 (1971).